Education
About Us
Working with TipRanks
Follow Us
Mabion SA (PL:MAB)
:MAB
MAB Stock Chart & Stats
zł7.14
--
Market closed
zł7.14
--
Day’s Range― - ―
52-Week Rangezł6.95 - zł11.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)38.65K
Market Cap
€131.24M
Enterprise Valuezł152.41M
Total Cash (Recent Filing)€23.69M
Total Debt (Recent Filing)€3.56M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding16,162,327
10 Day Avg. Volume25,807
30 Day Avg. Volume38,648
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.29
Price to Sales (P/S)2.08
P/FCF Ratio5.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MAB FAQ
What was Mabion SA’s price range in the past 12 months?
Mabion SA lowest stock price was zł6.95 and its highest was zł11.80 in the past 12 months.
What is Mabion SA’s market cap?
Mabion SA’s market cap is €131.24M.
When is Mabion SA’s upcoming earnings report date?
Mabion SA’s upcoming earnings report date is May 21, 2026 which is in 168 days.
How were Mabion SA’s earnings last quarter?
Mabion SA released its earnings results on Nov 04, 2025. The company reported -zł0.665 earnings per share for the quarter, missing the consensus estimate of N/A by -zł0.665.
Is Mabion SA overvalued?
According to Wall Street analysts Mabion SA’s price is currently Overvalued.
Does Mabion SA pay dividends?
Mabion SA does not currently pay dividends.
What is Mabion SA’s EPS estimate?
Mabion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabion SA have?
Mabion SA has 16,162,327 shares outstanding.
What happened to Mabion SA’s price movement after its last earnings report?
Mabion SA reported an EPS of -zł0.665 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Mabion SA?
Currently, no hedge funds are holding shares in PL:MAB
Company Description
Mabion SA
Mabion SA (MAB) is a biotechnology company based in Poland, specializing in the development and production of biopharmaceuticals, particularly monoclonal antibodies. The company operates primarily in the biopharmaceutical sector, focusing on innovative treatments for various diseases, including cancer and autoimmune disorders. Mabion's core products include biosimilars and proprietary biologics, aimed at improving patient outcomes while reducing healthcare costs.
Technical Analysis
Ryvu Therapeutics SA
―
Scope Fluidics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―